DK0573527T3 - Fremstilling og anvendelse af formalindræbte, kolonisationsfaktor-antigen(CFA)-udtrykkende E. coli-organismer til vaccinati - Google Patents

Fremstilling og anvendelse af formalindræbte, kolonisationsfaktor-antigen(CFA)-udtrykkende E. coli-organismer til vaccinati

Info

Publication number
DK0573527T3
DK0573527T3 DK92906078T DK92906078T DK0573527T3 DK 0573527 T3 DK0573527 T3 DK 0573527T3 DK 92906078 T DK92906078 T DK 92906078T DK 92906078 T DK92906078 T DK 92906078T DK 0573527 T3 DK0573527 T3 DK 0573527T3
Authority
DK
Denmark
Prior art keywords
coli
formalin
expressing
colonization factor
cfa
Prior art date
Application number
DK92906078T
Other languages
English (en)
Inventor
Jan Holmgren
Original Assignee
Jan Holmgren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jan Holmgren filed Critical Jan Holmgren
Application granted granted Critical
Publication of DK0573527T3 publication Critical patent/DK0573527T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92906078T 1991-02-26 1992-02-25 Fremstilling og anvendelse af formalindræbte, kolonisationsfaktor-antigen(CFA)-udtrykkende E. coli-organismer til vaccinati DK0573527T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100556A SE9100556D0 (sv) 1991-02-26 1991-02-26 Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
PCT/SE1992/000110 WO1992014487A1 (en) 1991-02-26 1992-02-25 Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans

Publications (1)

Publication Number Publication Date
DK0573527T3 true DK0573527T3 (da) 1999-06-07

Family

ID=20381987

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92906078T DK0573527T3 (da) 1991-02-26 1992-02-25 Fremstilling og anvendelse af formalindræbte, kolonisationsfaktor-antigen(CFA)-udtrykkende E. coli-organismer til vaccinati

Country Status (22)

Country Link
US (1) US6558678B1 (da)
EP (1) EP0573527B1 (da)
JP (1) JP3169608B2 (da)
KR (1) KR100221452B1 (da)
AT (1) ATE170755T1 (da)
AU (1) AU663864B2 (da)
BG (1) BG61683B1 (da)
BR (1) BR9205677A (da)
CA (1) CA2104877C (da)
CZ (1) CZ281556B6 (da)
DE (1) DE69226944T2 (da)
DK (1) DK0573527T3 (da)
ES (1) ES2123550T3 (da)
FI (1) FI108775B (da)
HU (1) HU213924B (da)
NO (1) NO307867B1 (da)
OA (1) OA09865A (da)
RO (1) RO109819B1 (da)
RU (1) RU2127121C1 (da)
SE (1) SE9100556D0 (da)
SK (1) SK280919B6 (da)
WO (1) WO1992014487A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
SE9401921D0 (sv) * 1994-06-03 1994-06-03 Sbl Vaccin Ab A method of cultivating bacteria
US7404961B2 (en) 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
US7094883B1 (en) 1996-08-02 2006-08-22 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein
US5994078A (en) * 1997-07-31 1999-11-30 Maine Medical Center Stable encapsulated reference nucleic acid and method of making
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
CA2543763A1 (en) * 2003-10-31 2005-05-12 The University Of British Columbia Bacterial virulence factors and uses thereof
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
JPWO2012157699A1 (ja) * 2011-05-18 2014-07-31 味の素株式会社 動物用免疫賦活剤、それを含む飼料及びその製造方法
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
KR101940357B1 (ko) 2011-09-12 2019-01-18 스칸디나비안 바이오파마 홀딩 에이비 세포 표면 상 ｅｔｅｃ ｃｓ６ 항원 제시의 증가 방법 및 그것의 수득가능한 산물들
AU2011376755B2 (en) * 2011-09-12 2016-09-29 Scandinavian Biopharma Holding Ab Vaccine for protection against ETEC induced diarrhea comprising dmLT.
RO132299A3 (ro) 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD62894A (da) *
DE1208038B (de) * 1963-08-01 1965-12-30 Wellcome Found Verfahren zur Herstellung von Impfstoffen gegen Coli-Infektionen
GB1472624A (en) * 1974-09-02 1977-05-04 Canadian Patents Dev Enteric disease vaccine
US4298597A (en) * 1979-09-04 1981-11-03 University Of Saskatchewan Vaccine for diarrhea caused by E. coli
US4338298A (en) * 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
DK41885A (da) * 1985-01-31 1986-11-13 Slagteriernes Forskningsinst 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen
IL79432A (en) * 1985-07-31 1992-05-25 Univ Leland Stanford Junior Unicellular microorganisms having invasive capability due to exogenous inv gene and vaccines comprising such microorganisms
FI76484C (fi) 1986-02-03 1988-11-10 Osmo Norvasto Kundstol.
JPS6399020A (ja) * 1986-06-05 1988-04-30 ベイラ−　カレツジ　オブ　メデイシン ワクチンとその製法
SU1723116A1 (ru) * 1988-04-15 1992-03-30 Оренбургский Государственный Медицинский Институт Штамм бактерий BacILLUS SUвтILIS, используемый дл получени препарата дл профилактики и лечени воспалительных процессов и аллергических заболеваний
IL91525A0 (en) * 1988-09-06 1990-04-29 Univ Washington Transgenic plants,pharmaceutical compositions containing the same and methods for the preparation thereof
SE9401921D0 (sv) * 1994-06-03 1994-06-03 Sbl Vaccin Ab A method of cultivating bacteria

Also Published As

Publication number Publication date
NO307867B1 (no) 2000-06-13
HUT67198A (en) 1995-02-28
WO1992014487A1 (en) 1992-09-03
JP3169608B2 (ja) 2001-05-28
FI933728L (fi) 1993-10-25
DE69226944D1 (de) 1998-10-15
FI108775B (fi) 2002-03-28
JPH06505730A (ja) 1994-06-30
BG61683B1 (bg) 1998-03-31
BG98070A (bg) 1994-06-30
EP0573527A1 (en) 1993-12-15
CZ281556B6 (cs) 1996-11-13
CZ174293A3 (en) 1994-04-13
ES2123550T3 (es) 1999-01-16
RU2127121C1 (ru) 1999-03-10
AU1330892A (en) 1992-09-15
OA09865A (en) 1994-08-15
CA2104877C (en) 2005-10-04
CA2104877A1 (en) 1992-08-27
RO109819B1 (ro) 1995-06-30
SK280919B6 (sk) 2000-09-12
NO933037D0 (no) 1993-08-25
DE69226944T2 (de) 1999-02-11
KR930703015A (ko) 1993-11-29
ATE170755T1 (de) 1998-09-15
BR9205677A (pt) 1994-05-17
HU213924B (en) 1997-11-28
SE9100556D0 (sv) 1991-02-26
AU663864B2 (en) 1995-10-26
NO933037L (no) 1993-08-25
FI933728A0 (fi) 1993-08-25
HU9302410D0 (en) 1993-11-29
EP0573527B1 (en) 1998-09-09
US6558678B1 (en) 2003-05-06
SK91093A3 (en) 1994-05-11
KR100221452B1 (ko) 1999-09-15

Similar Documents

Publication Publication Date Title
SE9100556D0 (sv) Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
Germanier Immunity in experimental salmonellosis III. Comparative immunization with viable and heat-inactivated cells of Salmonella typhimurium
Lindberg et al. Development of an auxotrophic oral live Shigella flexneri vaccine
EP1702927B1 (en) Attenuated microorganisms for the treatment of infection
Morris Jr et al. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers
CA2132836A1 (en) Immunization by inoculation of dna transcription unit
RU93053899A (ru) Способ получения композиции вакцины, способ профилактики кишечных инфекций
JPS58501325A (ja) 腸疾患用免疫賦与性経口ワクチン
US20040037851A1 (en) Fusobacterium necrophorum vaccine and method for making such vaccine
Bratthall et al. Antigenic variation of Streptococcus mutans colonizing gnotobiotic rats
Woodward Volunteer studies of typhoid fever and vaccines
Mukhopadhaya et al. Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response
Gaines et al. STUDIES ON INFECTION AND IMMUNITY IN EXPERIMENTAL TYPHOID FEVER: III. EFFECT OF PROPHYLACTIC IMMUNIZATION
Xing et al. Nitric oxide induction in murine macrophages and spleen cells by whole-cell Bordetella pertussis vaccine
RU2058388C1 (ru) Штамм бактерий vibrio cholerae eltor jnaba, используемый для иммунопрофилактики холеры
Boesman-Finkelstein et al. Protection in rabbits induced by the Texas Star-SR attenuated A-B+ mutant candidate live oral cholera vaccine
Shaughnessy et al. Production of Potent Inactivated Vaccines with Ultraviolet Irradiation: IV. Vaccination Against Bacillary Dysentery
EP0686039A1 (en) Method of enhancing immune response to oral vaccines
Guinée et al. Protective immunity against Vibrio cholerae infection in the rabbit
Yancey et al. Motility of the pathogen and intestinal immunity of the host in experimental cholera
MICHEL Failure of anti-furunculosis vaccination of rainbow trout (Salmo gairdneri Richardson), using extra-cellular products of Aeromonas salmonicida as an immunogen
Pittman et al. Laboratory assay of cholera vaccine potency
Davis et al. Further observations on the use of a bivalent bacterin against Haemophilus gallinarum
Chen et al. Priming of Macaca cynomolgus philippinensis with purified antigen of Brucella melitensis before injection of Rev. I vaccine
Ada Desirable immunologic characteristics for the development of an ideal vaccine